4,5-bis<4-(methylthio)phenyl>-1H-imidazole-2-thiol | 66659-98-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4,5-bis<4-(methylthio)phenyl>-1H-imidazole-2-thiol
• 英文别名: 4,5-bis-(4-methylsulfanyl-phenyl)-1,3-dihydro-imidazole-2-thione；4,5-bis(p-methylthiophenyl)-2-mercaptoimidazole；4,5-Bis-(p-methylthiophenyl)-2-mercaptoimidazole；4,5-bis(4-methylsulfanylphenyl)-1,3-dihydroimidazole-2-thione
• CAS: 66659-98-1
• 化学式: C₁₇H₁₆N₂S₃
• 分子量: 344.525
• InChiKey: PFCBNIAUGCRXPR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  107
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-<2-(2-ethoxyethoxy)ethyl>-5-bromopentanamide 、 4,5-bis<4-(methylthio)phenyl>-1H-imidazole-2-thiol 在 potassium carbonate 、 sodium iodide 作用下， 以 四氢呋喃 为溶剂， 反应 16.0h， 以66%的产率得到N-<2-(2-ethoxyethoxy)ethyl>-5-<<4,5-bis<4-(methylthio)phenyl>-1H-imidazol-2-yl>thio>pentanamide
  参考文献：
  名称：

  新的咪唑系列J774巨噬细胞特异性酰基辅酶A：胆固醇酰基转移酶（ACAT）抑制剂的设计，合成和结构-活性关系研究。

  摘要：

  酰基辅酶A：胆固醇酰基转移酶（ACAT）是参与细胞内胆固醇酯化的主要酶。巨噬细胞的动脉壁浸润和随后的胆固醇不受控制的酯化导致泡沫细胞形成被认为是导致脂肪条纹发展的重要过程。ACAT酶的抑制剂可能会延迟该动脉粥样硬化过程。我们最近发现了一系列咪唑，它们在J774巨噬细胞细胞培养测定中是有效的体外ACAT抑制剂。本文将描述这一系列非常有效的化合物的设计，合成和结构-活性关系。

  DOI：

  10.1021/jm00007a004
• 作为产物：
  描述：

  2-hydroxy-1,2-bis(4-methylsulfanyl-phenyl)ethanone 在 硫脲 作用下， 生成 4,5-bis<4-(methylthio)phenyl>-1H-imidazole-2-thiol
  参考文献：
  名称：

  5,6-Phenyl-2,3-dihydroimidazo [2,1-b] thiazoles

  摘要：

  这些化合物是5,6-苯基-2,3-二氢咪唑[2,1-b]噻唑的衍生物，具有抗关节炎活性。其中一种优选的化合物是5,6-双(对甲氧基苯基)-2,3-二氢咪唑[2,1-b]噻唑。

  公开号：

  US04263311A1

文献信息

• 2,2-Alkyldiylbis(thio)bis(imidazoles)
  申请人：SmithKline Corporation

  公开号：US04188397A1

  公开（公告）日：1980-02-12

  New 2,2'-alkyldiylbis(thio)bis(imidazoles) having substituted phenyl groups in the 4- and 5- positions of the imidazole rings are disclosed. These compounds regulate cell-mediated immunity and/or have anti-arthritic activity and are useful to relieve inflammation, for example in the treatment of rheumatoid arthritis.

  本发明揭示了4-和5-位置在咪唑环上具有取代苯基的新型2,2'-烷基二硫基双咪唑化合物。这些化合物能够调节细胞介导的免疫反应和/或具有抗关节炎活性，并且可用于缓解炎症，例如治疗类风湿性关节炎。
• Bis-imidazoles, their preparation and pharmaceutical compositions containing them
  申请人：SMITHKLINE BECKMAN CORPORATION

  公开号：EP0010361A1

  公开（公告）日：1980-04-30

  The use is disclosed of compounds of the formula (I):- where R' is methoxy, methylthio, trifluoromethyl, chloro, fluoro or bromo; R2 is hydrogen or with R1 is methylenedioxy; R3 is hydrogen or methyl; n is 0, 1 or 2; andX is -(CH2)m- where m is 0 to 4, 1,2-propanediyl, 1,3-propan-2 -oldiyl or 1,3-propan -2-onediyl and their pharmaceutically acceptable salts, provided that m is not 0 when R1 is chloro, as anti-arthritic agents. Also disclosed are pharmaceutical compositions comprising a compound of formula (I) as defined above or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier. Some compounds of formula (I) are novel, such compounds have formula (I) where R' is methoxy, methylthio, trifluro-methyl, chloro, fluoro or brom; R2 is hydrogen or with R1 is methylenedioxy; R3 is hydrogen or methyl; n is 0, 1 or2; and X is -(CH2)m- where m is 0 to 4, 1,2-propanediyl, 1,3-propan-2 -oldiyl or 1,3-propan-2-onediyl, and pharmaceutically acceptable salts, provided that when R1 is chlorom is not 0 and when R1 is methoxy and n is 0 m is not 2. A process is disclosed for the preparation of these novel compounds.

  本发明公开了式(I)化合物的用途 其中 R'是甲氧基、甲硫基、三氟甲基、氯、氟或溴；R2 是氢或与 R1 一起是亚甲基二氧基；R3 是氢或甲基；n 是 0、1 或 2；和 X 是-(CH2)m-（其中 m 为 0 至 4）、1,2-丙二基、1,3-丙-2-烯二基或 1,3-丙-2-壬二基及其药学上可接受的盐，条件是当 R1 为氯时，m 不为 0，作为抗关节炎剂。还公开了药物组合物，其中包含如上定义的式 (I) 化合物或其药学上可接受的盐以及药学上可接受的载体。 一些式 (I) 的化合物是新型的，此类化合物具有式 (I) 其中 R' 是甲氧基、甲硫基、三氟甲基、氯、氟或溴；R2 是氢或与 R1 一起是亚甲基二氧基；R3 是氢或甲基；n 是 0、1 或 2；和 X 是-(CH2)m-（其中 m 为 0 至 4）、1,2-丙二基、1,3-丙-2-烯二基或 1,3-丙-2-壬二基，以及药学上可接受的盐，条件是当 R1 为氯时，m 不为 0，当 R1 为甲氧基且 n 为 0 时，m 不为 2。本发明公开了制备这些新型化合物的工艺。
• 5,6-Diaryl-2,3-dihydroimidazo[2,1-b]thiazoles: a new class of immunoregulatory antiinflammatory agents
  作者：Paul E. Bender、David Hill、Priscilla H. Offen、Kazys Razgaitis、Patricia Lavanchy、Orum D. Stringer、Blaine M. Sutton、Don E. Griswold、Michael DiMartino

  DOI：10.1021/jm00147a008

  日期：1985.9

  A series of substituted 5,6-diaryl-2,3-dihydroimidazo[2,1-b]thiazoles were synthesized and evaluated in the rat adjuvant-induced arthritis and mouse oxazolone-induced contact sensitivity assays to determine the potential of these compounds for use as immunoregulatory antiinflammatory agents. This class of compounds was derived by combining salient structural features of the antiinflammatory agent flumizole and the immunoregulatory drug levamisole. Unlike the latter two, a number of compounds in the target series were found to possess the desired combination of activities. Exploration of structure-activity relationships in the adjuvant-induced arthritic rat assay revealed that optimal potency was exhibited by symmetrically substituted 5,6-diaryl compounds having one of the following alkyl heteroatom or halogen functions at the para position: methoxy, ethoxy, methylthio, N-ethyl-N-methylamino, fluoro, or chloro. Scrambling of these two substituent classes to yield the asymmetrically substituted 5,6-diaryl compounds resulted in potent activity only with the 5-alkyl heteroatom, 6-halo-substituted regioisomers. However in the oxazolone-induced contact sensitivity assay, no consistent relationship of variation in activity with structural change was apparent. The initial target compound 5,6-bis(4-methoxyphenyl)-2,3-dihydroimidazo[2,1-b]thiazole (1) was compared with its progenitors in additional models of inflammation and immunoregulation.
• BENDER, P. E.;HILL, D. T.;OFFEN, P. H.;RAZGAITIS, K.;LAVANCHY, P.;STRINGE+, J. MED. CHEM., 1985, 28, N 9, 1169-1177
  作者：BENDER, P. E.、HILL, D. T.、OFFEN, P. H.、RAZGAITIS, K.、LAVANCHY, P.、STRINGE+

  DOI：——

  日期：——
• US4188397A
  申请人：——

  公开号：US4188397A

  公开（公告）日：1980-02-12